

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>06666-022002</b>	Application No. <b>10/045,178</b>
	Applicant <b>Noriyuki Kasahara et al.</b>		
	Filing Date <b>January 11, 2002</b>	Group Art Unit <b>1632</b>	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/IP/	AA	6,033,902	03-07-2000	Haseltine et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

Other Documents (Include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/IP/	AQ	Jolly, Viral vector systems for gene therapy. <i>Cancer Gene Therapy</i> 1:51-64 (1994)
/IP/	AR	Miller Targeted vectors for gene therapy. <i>The FASEB Journal</i> 9:190-9 (1995)
/IP/	AS	Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy. <a href="http://www.nih.gov">www.nih.gov</a> December 1995
J.P.	AT	Verma et al., Gene therapy-promises, problems and prospects. <i>Nature</i> 389:239-242 (1997)

02/10/02

Examiner Signature  /Ileana Popa/	Date Considered  03/29/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	